Comparative analysis of the safety and efficacy of 1470-nm diode laser enucleation of the prostate and plasmakinetic resection of prostate in the treatment of large volume benign prostatic hyperplasia (>80 ml)

References

• Devlin CM, Simms MS, Maitland NJ. Benign prostatic hyperplasia—what do we know? BJU Int. 2021;127(4):389–399. doi: 10.1111/bju.15229.
   PubMed Web of Science ®Google Scholar
• Rassweiler J, Teber D, Kuntz R, et al. Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol. 2006;50(5):969–979. doi: 10.1016/j.eururo.2005.12.042.
   PubMed Web of Science ®Google Scholar
• Nair SM, Pimentel MA, Gilling PJ. A review of laser treatment for symptomatic BPH (benign prostatic hyperplasia). Curr Urol Rep. 2016;17(6):45. doi: 10.1007/s11934-016-0603-5.
   PubMed Web of Science ®Google Scholar
• Ottaiano N, Shelton T, Sanekommu G, et al. Surgical complications in the management of benign prostatic hyperplasia treatment. Curr Urol Rep. 2022;23(5):83–92. doi: 10.1007/s11934-022-01091-z.
   PubMed Web of Science ®Google Scholar
• Xu X, Jiang D, Liu G, et al. In vitro evaluation of the safety and efficacy of a high-power 450-nm semiconductor blue laser in the treatment of benign prostate hyperplasia. Lasers Med Sci. 2022;37(1):555–561. doi: 10.1007/s10103-021-03297-y.
   PubMed Web of Science ®Google Scholar
• He G, Shu Y, Wang B, et al. Comparison of diode laser (980 nm) enucleation vs holmium laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized controlled trial with 12-month follow-up. J Endourol. 2019;33(10):843–849. doi: 10.1089/end.2019.0341.
   PubMed Web of Science ®Google Scholar
• Popov SV, Orlov IN, Martov AG, et al. A comparison between enucleation of the prostate using holmium and thulium laser in volume over 80 cc: retrospective clinical study with 12-months follow-up. Urologiia. 2019;3_2019:80–83. (doi: 10.18565/urology.2019.3.80-83.
   Google Scholar
• Zhao C, Yang H, Chen Z, et al. Thulium laser resection versus plasmakinetic resection of prostates in the treatment of benign prostate hyperplasia: a meta-analysis. J Laparoendosc Adv Surg Tech A. 2016;26(10):789–798. doi: 10.1089/lap.2016.0044.
   PubMed Web of Science ®Google Scholar
• Peng B, Wang GC, Zheng JH, et al. A comparative study of thulium laser resection of the prostate and bipolar transurethral plasmakinetic prostatectomy for treating benign prostatic hyperplasia. BJU Int. 2013;111(4):633–637. doi: 10.1111/j.1464-410X.2012.11610.x.
   PubMed Web of Science ®Google Scholar
• Li S, Kwong JS, Zeng XT, et al. Plasmakinetic resection technology for the treatment of benign prostatic hyperplasia: evidence from a systematic review and meta-analysis. Sci Rep. 2015;5(1):12002. doi: 10.1038/srep12002.
   PubMedGoogle Scholar
• Xie T, Lai P, Luo M, et al. The effectiveness and safety of transurethral (bipolar) plasmakinetic resection of prostate combined with thulium laser for large benign prostatic hyperplasia (>80 ml). Urol J. 2016;13(6):2889–2892.
   PubMed Web of Science ®Google Scholar
• Zeng XT, Jin YH, Liu TZ, et al. Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia (2021 edition). Mil Med Res. 2022;9(1):14.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Bai X, Zhang X, et al. Comparative study of the effectiveness and safety of transurethral bipolar plasmakinetic enucleation of the prostate and transurethral bipolar plasmakinetic resection of the prostate for massive benign prostate hyperplasia (>80 ml). Med Sci Monit. 2020;26:e921272. doi: 10.12659/MSM.921272.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang X, Zhang Y, et al. 1470 nm diode laser enucleation vs plasmakinetic resection of the prostate for benign prostatic hyperplasia: a randomized study. J Endourol. 2019;33(3):211–217. doi: 10.1089/end.2018.0499.
   PubMed Web of Science ®Google Scholar
• Mu X, Guo L, Guo Z, et al. Diode laser enucleation vs. Bipolar transurethral enucleation of prostate for benign prostatic hyperplasia: a retrospective comparative study with three-year follow up. Arch Esp Urol. 2023;76(2):161–168. doi: 10.56434/j.arch.esp.urol.20237602.18.
   PubMed Web of Science ®Google Scholar
• Zhou R, Che X, Zhou Z, et al. A systematic review and meta-analysis of the efficacy and safety of tamsulosin plus tadalafil compared with tamsulosin alone in treating males with lower urinary tract symptoms secondary to benign prostrate hyperplasia. Am J Mens Health. 2023;17(1):15579883231155096. doi: 10.1177/15579883231155096.
   Web of Science ®Google Scholar
• Calogero AE, Burgio G, Condorelli RA, et al. Epidemiology and risk factors of lower urinary tract symptoms/benign prostatic hyperplasia and erectile dysfunction. Aging Male. 2019;22(1):12–19. doi: 10.1080/13685538.2018.1434772.
   PubMed Web of Science ®Google Scholar
• Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2004;6 (Suppl 9):S3–S10.
   Google Scholar
• Dobrek Ł, Thor PJ. Benign prostatic hyperplasia—progress in pathophysiology and management. Pol Merkur Lekarski. 2015;39(233):263–270.
   PubMedGoogle Scholar
• Kim EH, Larson JA, Andriole GL. Management of benign prostatic hyperplasia. Annu Rev Med. 2016;67(1):137–151. doi: 10.1146/annurev-med-063014-123902.
   PubMedGoogle Scholar
• Plochocki A, King B. Medical treatment of benign prostatic hyperplasia. Urol Clin North Am. 2022;49(2):231–238. doi: 10.1016/j.ucl.2021.12.003.
   PubMed Web of Science ®Google Scholar
• Knight GM, Talwar A, Salem R, et al. Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia. Cardiovasc Interv Radiol. 2021;44(2):183–193. doi: 10.1007/s00270-020-02657-5.
   PubMed Web of Science ®Google Scholar
• Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. Dtsch Arztebl Int. 2020;117(49):843–854.
   PubMed Web of Science ®Google Scholar
• Das AK, Teplitsky S, Humphreys MR. Holmium laser enucleation of the prostate (HoLEP): a review and update. Can J Urol. 2019;26:13–19.
   PubMed Web of Science ®Google Scholar
• Shao D, Zang Z, Li Z, et al. Efficacy and safety of 1470 nm diode laser enucleation of the prostate in elderly benign prostatic hyperplasia patients. J Endourol. 2023;37(6):700–705. doi: 10.1089/end.2022.0705.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhao Y, Wang X, et al. Critical reviews of 1470-nm laser vaporization on benign prostatic hyperplasia. Lasers Med Sci. 2018;33(2):323–327. doi: 10.1007/s10103-017-2377-5.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Liu C, Zhou G, et al. A retrospective evaluation of benign prostatic hyperplasia treatment by transurethral vaporization using a 1470 nm laser. Photomed Laser Surg. 2013;31(12):626–629. doi: 10.1089/pho.2013.3504.
   PubMed Web of Science ®Google Scholar
• Song Y, Pang S, Luo G, et al. Comparison of PKRP and TUVP in the treatment of high-risk BPH and analysis of postoperative influencing factors. Front Surg. 2022;9:947027. doi: 10.3389/fsurg.2022.947027.
   PubMed Web of Science ®Google Scholar
• Sascha AA, Peter G, Steven AK. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010;58(3):384–397.
   PubMed Web of Science ®Google Scholar
• Liu S, Zhang BY, Xiao B, et al. Research progress on long-term complications of transurethral resection, enucleation, and dilation in the treatment of benign prostatic hyperplasia. Chin J Endosc Urol. 2022;8(16):377–380.
   Google Scholar
• Sandhu JS, Breyer B, Comiter C, et al. Incontinence after prostate treatment: AUA/SUFU guideline. J Urol. 2019;202(2):369–378. doi: 10.1097/JU.0000000000000314.
   PubMed Web of Science ®Google Scholar